Clinical data | |
---|---|
Other names | MY400 |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C12H15NS |
Molar mass | 205.32 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
5-MAPBT (5-methylaminopropylbenzothiophene) is an empathogenic drug of the benzothiophene group. It is closely related to 5-MAPB but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.
It has been patented by Tactogen as an entactogen for potential use as a medicine.
See also
References
- Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
- ^ WO 2022/010937, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement.", published 13 January 2022, assigned to Tactogen Inc.
Empathogens/entactogens | |
---|---|
Phenylalkyl- amines (other than cathinones) |
|
Cyclized phenyl- alkylamines | |
Cathinones | |
Tryptamines | |
Chemical classes |